key: cord-0309714-9rxgi6pu authors: Isitt, C.; Sjoholm, D.; Hergens, M.-P.; Granath, F.; Naucler, P. title: The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden date: 2021-09-07 journal: nan DOI: 10.1101/2021.09.02.21263046 sha: ca30f542b6f302f4c3a624886cfb65d3dc1ba3f4 doc_id: 309714 cord_uid: 9rxgi6pu Vaccination against SARS-CoV-2 started in Region Stockholm, Sweden in December 2020 with those in long-term care facilities or receiving home care vaccinated first followed by those aged over 80 years. In this population-based, retrospective cohort study, we performed a Poisson regression to model the expected incidence of infections and deaths which we compared to the observed incidence and compared this to an unvaccinated control group of those aged 18-79 years. The aim of this study was to measure the early impact of the vaccination programme in Region Stockholm. Infections and deaths reduced substantially amongst the first two groups targeted for SARS-CoV-2 vaccination with an estimated total 3112 infections prevented, and 854 deaths prevented in these two groups from 4 weeks after the introduction of vaccination through to 2nd May 2021. The Swedish COVID-19 vaccination programme prioritises those most at risk of severe The Stockholm COVID-19 cohort study collects data from all residents living in Region Stockholm from 2015 onwards. We extracted data from the VAL database which collates 57 information from more than ten other healthcare related databases in Region Stockholm and 58 which has been previously described [4] . Age, and coding for resident in LTCF and home care 59 were used to define the two groups first targeted for vaccination, those in LTCF/home care 60 and those aged ≥80 years, plus a third group, those aged 18-79 years who were used as a 61 composite unvaccinated control. Linkage to SmiNet, the Public Health Agency of Sweden 62 notifiable infection reporting tool, was performed using unique personal identification numbers 63 that each resident in Sweden has, to extract data on SARS-CoV-2 PCR-positive cases. The study was approved by the Swedish Ethical Review Authority. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The highest number of infections (182,695) were in the control group (18-79 year-olds) ( Table 105 2). More infections were recorded in the LTCF/home care group (6769 total; 5232 pre-106 vaccination, 1537 post-vaccination) than in the 80+ group (2464 total; 2276 pre-vaccination, 107 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 7, 2021. At risk plots: 2 week rolling average, population censored upon a positive test or 31d after a positive test, respectively. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 7, 2021. ; https://doi.org/10.1101/2021.09.02.21263046 doi: medRxiv preprint Our data suggests that vaccination of the LTCF/home care and 80+ groups succeeded in 158 preventing a third wave in these groups of the same magnitude as the control group. Since perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in An additional limitation in our study is that vaccine coverage data was based on LTCF and 197 age, since data for those receiving home care was not available whereas incidence of perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted September 7, 2021. Nationell plan för vaccination mot covid-19 Dagsläge covid-19 Information om vaccination med Astra Zenecas vaccin till 229 personer som är 65 år och äldre Folkhälsomyndighetens föreskrifter och allmänna råd om 241 allas ansvar att förhindra smitta av covid-19 m.m., 2020. 242 Samtliga godkända vacciner mot covid-19 skyddar mot 251 sjukdom Om vaccinerna mot covid-19 Rekommendation om åldersgräns på 65 år för AstraZenecas 259 vaccin kvarstår Om vaccinerna mot covid-19 Jamie 270 Lopez Bernal, Impact of COVID-19 vaccines on mortality in England preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in